Reproduction and Fertility is an open-access, peer-reviewed journal
Page URL:

Loan from potential buyer will save deCODE from liquidation, says founder

30 November 2009
Appeared in BioNews 536

Dr Kari Stefansson, founder of biopharmaceutical company deCODE genetics, has claimed that the company will be able to continue normal services despite announcing bankruptcy last week.

DeCODE was founded in 1996 by Dr Stefansson, a Harvard neurological researcher who aimed to establish a business that was profitable in both an academic and financial sense. By utilising the extensive medical records of the small, genetically isolated Icelandic population, deCODE hoped to probe for and identify key genetic markers of common diseases, discover the gene function and then develop targeted and personalised treatments for patients. The company has had great academic success but has never managed to turn a profit due to its research not translating to successful drug development. DeCODE reported  problems a year ago and since then has been attempting to sell parts of the business to recoup some of the financial losses.

Last summer there were rumours of a deal being made with the biomedical charity, The Wellcome Trust. A supposed offer was made by the trust which would enable it to take over deCODE's extensive biobank but no such deal ever materialised. This was thought by some to be because of deCODE's restrictions on data sharing but Dr Stefansson claimed it was due to the nature of how the deCODE company has to function. The Wellcome Trust wanted deCODE to become a non-profitable academic institute but this is not possible as deCODE has responsibilities to its shareholders.

An investment company known as Saga has now reportedly offered $14 million for deCODE's drug development and discovery branches. The offer has to be accepted by the courts and Stefansson is optimistic a decision will be made by January next year. At the moment Stefansson has said he is hoping to remain a prominent figure in the company working as executive chair and head of research whilst someone else would take over as CEO to lead commercial projects. Stefansson believes that deCODE is still needed and has said he aims to have 2500 entire genomes sequenced by mid-2011 in order to identify rare variants of mutations which could confer higher prevalence of disease. Other researchers have commented that as the database deCODE uses is that of a close knit, homogenous population the company stands a good chance of finding important rare variants.

Bankruptcy Won’t Stop deCODE, Says Its Founder, Stefánsson
Science magazine |  27 November 2009
17 December 2012 - by Holly Rogers 
The US biotechnology company Amgen will buy deCODE Genetics, which provides products and services for genome analysis, for $415 million...
25 January 2010 - by Nishat Hyder 
The pioneering genetics research company, deCODE, reemerged last week as a private company with new financial backing. Based in Reykjavik, Iceland, the original company deCODE Genetics, Inc led the way internationally in genetic testing and diagnostics for over a decade. With unique access to genetic information from Iceland's isolated population, the biotech firm has made important discoveries, such as identifying gene variants associated with common conditions ...
30 November 2009 - by Dr Jess Buxton 
After almost ten happy years as a BioNews editor, this issue will be my last. I started working for Progress Educational Trust (PET) in February 2000, nearly a year after BioNews was launched by Juliet Tizzard, the first PET director. In my first week, I remember thinking how useful a news digest of developments in the fast-moving areas of genetics and assisted reproduction was - and what a fascinating job it was going to be. But at the same time, I privately wondered whether there would be q...
22 November 2009 - by Dr Jay Stone 
The commercialisation of 'personalised' genetic medicine was delivered a blow last week as the Icelandic biopharmaceutical company deCODE genetics was forced to file for bankruptcy. The company was reported to be restructuring but are now considering an offer from Saga investment for their drug development branch and have been forced to put their other assets up for sale also....
14 April 2009 - by MacKenna Roberts 
The impending financial demise of leading human genetics biotechnology company deCODE Genetics is seen as a direct blow to genetic medicine and ultimately signalling wider ramifications for the impact of the global financial crisis on the genomics industry as a whole. Chief executive Kari Stefansson announced, on...
26 November 2007 - by Ailsa Stevens 
Two rival companies have launched novel genetic services which, for a price tag of $1000 (£483), will allow people to have their genomes scanned, delivering them personal information about their ancestry, some personal disease risks and other inherited traits. The first - called deCODEme - was launched by Icelandic...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.